Asconapé, JJ, Penry, JK, Dreifuss, FE, Riela, A, Mirza, W. Valproate-associated pancreatitis. Epilepsia 1993; 34: 177–183.
Biton, V, Mirza, W, Montouris, G, Vuong, A, Hammer, AE, Barrett, PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001; 56: 172–177.
Bryant, AE, Dreifuss, FE. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 1996; 46: 465–469.
Glaucer, TA, Cnaan, A, Shinnar, S, Hirtz, DG, Dlugos, D, Masur, D, Clark, PO, Capparelli, EV, Adamson, PC. for the Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. New England Journal of Medicine 2010; 362: 790–799.
Hernandez-Diaz, S, Smith, CR, Shen, A, Mittendorf, R, Hauser, WA, Yerby, M, Holmes, LB. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012; 78: 1692–1699.
Limdi, NA, Shimpi, AV, Faught, E, Gomez, CR, Burneo, JG. Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology 2005; 64: 353–355.
Marson, AG, Al-Kharusi, AM, Alwaidh, M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369: 1016–1026.
Marson, AG, Williamson, PR, Clough, H, Hutton, JL, Chadwick, DW; Epilepsy Monotherapy Trial Group. Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia 2002; 43: 505–513.
Mattson, RH, Cramer, JA, Collins, JF; Dept. of VA Epilepsy Cooperative Study No. 264 Group. A comparison of valproate with carbamaze-pine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. New England Journal of Medicine 1992; 327: 765–771.
Meador, KJ, Baker, GA, Browning, N, Clayton-Smith, J, Combs-Cantrell, DT, Cohen, M, Kalayjian, LA, Kanner, A, Liporace, JD, Pennell, PB, Privitera, M, Loring, DW. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. New England Journal of Medicine 2009; 360: 1597–1605.
Patsalos, PN. Antiepileptic drug interactions: a clinical guide, 3rd edition. Springer, London, UK; 2016.
Patsalos, PN, Berry, DJ, Bourgeois, BF, Cloyd, JC, Glauser, TA, Johannessen, SI, Leppik, IE, Tomson, T, Perucca, E. Antiepileptic drugs – best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239–1276.
Patsalos, PN, Zugman, M, Lake, C, James, A, Ratnaraj, N, Sander, JW. Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: a comparison of free non-protein-bound concentrations. Epilepsia 2017; 58: 1234–1243.
Ramsey, RE, Wilder, BJ, Murphy, JV, Holmes, GL, Uthman, B. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic-clonic seizures. Journal of Epilepsy 1992; 5: 55–60.
Shallcross, R, Bromley, RL, Irwin, B, Bonnett, LJ, Morrow, J, Baker, GA. Child development following in utero exposure. Levetiracetam vs sodium valproate. Neurology 2011; 76: 383–389.
Sommerville, KS, Dutta, S, Biton, V, Zhang, Y, Cloyd, JC, Uthman, B. Bioavailability of a Divalproex extended-release formulation versus the conventional Divalproex formulation in adult patients receiving enzyme-inducing antiepileptic drugs. Clinical Drug-Investigation 2003; 23: 661–670.
Vestergaard, P, Rejnmark, L, Mosekilde, L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004; 45: 1330–1337.
Villareal, HJ, Wilder, BJ, Willmore, LJ, Bauman, AW, Hammond, EJ, Bruni, J. Effect of valproic acid on spike and wave discharges in patients with absence seizures. Neurology 1978; 28: 886–891.
Wyszynski, DF, Nambisan, M, Surve, T, Alsdorf, RM, Smith, CR, Holmes, LB. Antiepileptic drug pregnancy registry. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005; 64: 961–965.